The Cytosolic Domain of Protein-tyrosine Kinase 7 (PTK7), Generated from Sequential Cleavage by a Disintegrin and Metalloprotease 17 (ADAM17) and γ-Secretase, Enhances Cell Proliferation and Migration in Colon Cancer Cells

Hye-Won Na1, Won-Sik Shin1, Andreas Ludwig2, and Seung-Taek Lee1,3

From the 1Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea and the 3Institute of Pharmacology and Toxicology, RWTH Aachen University, D-52074 Aachen, Germany

Background: A shedding product of PTK7 was detected in the culture media from colon cancer cells.

Results: PTK7 is sequentially processed by ADAM17 and γ-secretase, and its cytosolic domain enhances oncogenic properties of colon cancer cells.

Conclusion: The cytosolic domain of PTK7 generated by sequential cleavage of ADAM17 and γ-secretase promotes tumorigenesis.

Significance: We provide a novel oncogenic mechanism of PTK7 upon its processing.

Protein-tyrosine kinase 7 (PTK7) is a member of the defective receptor protein-tyrosine kinases and is known to function as a regulator of planar cell polarity during development. Its expression is up-regulated in some cancers including colon carcinoma. A 100-kDa fragment of PTK7 was detected in the culture media from colon cancer cells and HEK293 cells. The shed fragment was named sPTK7-Ig1–7 because its molecular mass was very similar to that of the entire extracellular domain of PTK7 that contains immunoglobulin-like loops 1 to 7 (Ig1–7). The shedding of sPTK7-Ig1–7 was enhanced by treatment with phorbol 12-myristate 13-acetate. In addition to the sPTK7-Ig1–7 found in the culture medium, two C-terminal fragments of PTK7 were detected in the cell lysates: PTK7-CTF1, which includes a transmembrane segment and a cytoplasmic domain, and PTK7-CTF2, which lacks most of the transmembrane segment from PTK7-CTF1. Analysis of PTK7 processing in the presence of various protease inhibitors or after knockdown of potential proteases suggests that shedding of PTK7 into sPTK7-Ig1–7 and PTK7-CTF1 is catalyzed by ADAM17, and further cleavage of PTK7-CTF1 into PTK7-CTF2 is mediated by the γ-secretase complex. PTK7-CTF2 localizes to the nucleus and enhances proliferation, migration, and anchorage-independent colony formation. Our findings demonstrate a novel role for PTK7 in the tumorigenesis via generation of PTK7-CTF2 by sequential cleavage of ADAM17 and γ-secretase.

Protein-tyrosine kinase 7 (PTK7)4 (also known as colon carcinoma kinase-4, CCK-4) is a receptor tyrosine kinase-like molecule containing an extracellular domain with seven immunoglobulin-like (Ig) loops, a transmembrane domain, and a catalytic domain lacking kinase activity (1–4). PTK7 is conserved across phylogenetically diverse groups from Hydra to human (5). Off-track (Dtrk/OTK), PTK7 ortholog in Drosophila was reported to be a hemophilic, Ca2+-independent cell adhesion molecule in the developing nervous system that regulates neuronal recognition and axon guidance (6). Later it was shown that Dtrk/OTK contributes to repulsive axon guidance signaling by associating with Plexins in response to semaphorin binding (7). In chickens, formation of a complex composed of Plexin-A1, KLG (PTK7 ortholog) and Sema6D is important for cardiac morphogenesis, especially the formation of the ventricle segment (8). In Xenopus, interaction between Plexin-A1 and PTK7 is required for neural crest migration (9).

A role of PTK7 as a regulator of planar cell polarity and non-canonical Wnt signaling was first identified in mice expressing a truncated form of PTK7. The mutation resulted in perinatal lethality, and the mice exhibited characteristic defects of planar cell polarity, such as open neural tubes and disorganized stereociliary bundle orientation (10). PTK7 regulates neural crest migration by recruiting Dishevelled to the membrane (11). PTK7 must interact with RACK1 to recruit Dishevelled for proper neural tube closure in Xenopus (12). Although a role for PTK7 in the canonical Wnt pathway has not been well defined, we have shown that Wnt3a-stimulated β-catenin/T cell factor transcriptional activity is weakened in PTK7-deficient cells

* This work was supported by grants from the Basic Research Program Grant 2009-007614-46, Studies on Ubiquitome Functions Grant 2005-2001143, and the Mid-Career Researcher Program Grant 2010-0026103 of the National Research Foundation, Ministry of Education, Science, and Technology, Republic of Korea and by the National R&D Program for Cancer Control Grant 1120110, Ministry of Health and Welfare, Republic of Korea (to S.-T.L.).

1 Predoctoral trainee of the Brain Korea 21 Program from Ministry of Education, Science, and Technology, Republic of Korea.
2 Supported by the Interdisciplinary Centre for Clinical Research (IZKF) Aachen.
3 To whom correspondence should be addressed. Tel.: 82-2-2123-2703; Fax: 82-2-362-9897; E-mail: stlee@yonsei.ac.kr.

4 The abbreviations used are: PTK7, protein-tyrosine kinase 7; ADAM, a disintegrin and metalloprotease; CTF, C-terminal fragment; ErbB, erythroidic leukemia viral oncogene homolog; I-Cip, intramembrane domain-cleaving protease; Ig, immunoglobulin-like; MMP, matrix metalloproteinase; MTT, 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide; OAK, off-track; PMA, phorbol 12-myristate 13-acetate; RIPA, radioimmuneprecipitation assay; sPTK7, soluble PTK7; TIMP, tissue inhibitor of metalloproteinases.
PTK7 Shedding and the Oncogenic Role of Its Cytosolic Domain

In contrast, Peradziryi et al. (14) reported that PTK7/Otk inhibits canonical Wnt signaling but activates noncanonical Wnt signaling by acting as a Frizzled co-receptor.

Up-regulation of PTK7 is observed in various cancers including colon cancer (2, 15), gastric cancer (16), lung cancer (17), acute myeloid leukemia (18), esophageal squamous cell carcinoma (19), and liposarcoma (20). Ectopic expression of PTK7 in leukemia cells promotes cell migration and survival, whereas knockdown of PTK7 shows the opposite effects (21). Knockdown of PTK7 in HCT-116 cells also inhibits cell proliferation and induces apoptosis (22). Similarly, knockdown of PTK7 in liposarcoma cells reduces cell proliferation and invasion and induces apoptosis (20). Interestingly, PTK7 was detected in an analysis of the secretome from pancreatic cancer cells (23) and colon cancer cells (24), suggesting the shedding of PTK7.

Shedding is an important regulatory mechanism for cellular signaling (25). Shedding of membrane proteins such as pro-TNF-α and heparin-binding EGF can release ligands inducing signal transduction (26). In contrast, shedding can down-regulate or terminate signaling by removing the signaling capability of proteins on the cell surface, like Ephrins, or by producing soluble decoy receptors that sequester cognate ligands, like sVEGFR-1 (27, 28). Sheddases that cleave extracellular domains are often members of a disintegrin and metalloprotease (ADAM) family or matrix metalloproteinase (MMP) family, which are Zn2+-dependent proteases. After cleavage of the extracellular domain by a sheddase, some cell surface receptors are further cleaved by intramembrane-cleaving proteases (I-CliPs) within the transmembrane domain in a process termed regulated intramembrane proteolysis. In some proteins such as Notch (29) and erythroblastic leukemia viral oncogene homolog 4 (ErbB4) (30), the cytosolic fragment generated by regulated intramembrane proteolysis can translocate to the nucleus and regulate transcription. In other proteins, the cytosolic fragments play various roles related to the function of the complete protein. The cytosolic domain of Ephrin-B2 activates Src by competing with Csk which phosphorylates and inhibits Src (31). Cleavage of E-cadherin by an I-Clip down-regulates cell adhesion and enhances Wnt signaling through the release of β-catenin (32).

In an attempt to understand the role of PTK7, we generated recombinant soluble PTK7 (sPTK7), which contains the entire extracellular domain consisting of Ig1–7 and acts as a decoy receptor to counteract PTK7 function. We previously demonstrated that treatment with sPTK7 induces an effect similar to PTK7 knockdown and inhibits VEGF-induced tube formation, migration, invasion of HUVECs, and VEGF-induced angiogenesis in vivo (33). ADAMs or MMPs that act as sheddases are often up-regulated during carcinogenesis. Thus, we hypothesized that sPTK7 may be generated in cancers by shedding of PTK7. In addition, MMP-14-dependent shedding of PTK7 was observed in breast cancer cells, and MMP-14 overexpression in fibrosarcoma HT-1080 cells induced the release of an extracellular domain of PTK7 containing the first six Ig loops (sPTK7-Ig1–6) (34). However, we found that, in colon cancer cells, PTK7 is shed into a form containing seven Ig loops, sPTK7-Ig1–7. Here, we report that in colon cancer cells PTK7 is sequentially processed in an extracellular cleavage event followed by intramembrane cleavage. We further demonstrate that the resulting cytosolic fragment of PTK7 has oncogenic properties.

EXPERIMENTAL PROCEDURES

Antibodies and Reagents—Mouse anti-human PTK7 monoclonal antibody against human sPTK7-His was generated and purified by Ab Frontier (Seoul, Korea). Anti-FLAG M2-agarose and the anti-FLAG M2 antibody were obtained from Sigma-Aldrich. Anti-GAPDH antibody was purchased from Ab Frontier. Anti-lamin A/C antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-TIMP-1 and anti-TIMP-2 were purchased from Calbiochem. Anti-TIMP-3, anti-TIMP-4, anti-ADAM10, and anti-ADAM17 antibodies were obtained from Millipore. GM6001 was from Santa Cruz Biotechnology and Chemicon. TAPI-1, pepstatin A, and E-64 were obtained from Calbiochem. DAPT and L-685458 were purchased from Sigma. Phorbol 12-myristate 13-acetate (PMA) was from A. G. Scientific (San Diego, CA). The hydroxamate-based ADAM inhibitors, GW280264X (selective for ADAM10 and ADAM17) and GI254023X (selective for ADAM10), were described previously (35, 36). siRNA pools for ADAM10 (M-004503-02), ADAM17 (s-003453–00), and negative control (s-001810-10) were purchased from Dharmacon (Chicago, IL).

Constructs for Expression of PTK7 or Its Domains—pcDNA3-hPTK7-FLAG, which expresses FLAG-tagged human PTK7, and pcDNA3-hPTK7-Ext-His, which expresses the His-tagged extracellular domain of PTK7, were described previously (33). To construct pcDNA3.1-PTK7-Cyt-FLAG, which expresses human PTK7 cytosolic domain containing residues 726–1070 of PTK7 and a C-terminal FLAG tag, the cDNA was PCR-amplified using pcDNA3-hPTK7-FLAG as a template and 5’-GTCGCTAGCATGTGCAAGAAGCGCTG-GCAAAGC-3’, including an Nhel site (italicized), a start codon (bold), and nucleotide positions of 2323–2342 of PTK7 cDNA (GenBank accession number U40271), and 5’-TGAAGGCGACACAGTCGAGG-3’, nucleotide positions 1036–1053 of pcDNA3 vector (Invitrogen), as primer pairs. The amplified fragments were digested with Nhel and EcoRI and ligated into pcDNA3.1. To generate pcDNA3.1-PTK7-CTF2-FLAG encoding residues 722–1070 of PTK7 and the C-terminal FLAG tag, nucleotides encoding residues 722–725 of PTK7 were inserted into pcDNA3.1-PTK7-Cyt-FLAG by DpnI-mediated site-directed mutagenesis method using a QuikChange kit (Stratagene) and 5’-GCAGTAGACATGAGCATGTGTTGCGCT-AGCCAGCTTGGGTCCTCCCTATAGTGA-3’ and 5’-GCGCCACCATGTCATGTTCTACACTGCAAGAAGCGCTGCAA-AGCCA-3’, including a Kozak’s consensus sequence (underlined), a start codon (bold), and nucleotide positions 2311–2325 of PTK7 cDNA (GenBank accession number U40271), as primers.

Cell Lines, Cell Culture, and Transfection—The colorectal cancer cell lines (HCT-8, HCT-15, HCT-116, SW480, DLD-1, LoVo, and HT-29) and HEK293 cells were cultured in DMEM supplemented with 10% FBS, 100 units/ml penicillin, and 100 µg/ml streptomycin. For transfection with plasmid DNA, subconfluent cells were transfected by the calcium phosphate method (37) followed by selection with 1.2 mg/ml G418. After 2
weeks, all colonies were cultured as a mixed population or individual clones. For transfection with siRNA (100 nM), subconfluent cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

**Immunoprecipitation and Western Blotting of Cell Lysates and Media**—Subconfluent cells were incubated in serum-free medium either for 8 h without PMA or for 30 min with 100 ng/ml PMA. To collect proteins secreted into the medium, the medium was spun down at 2,000 rpm for 5 min and then precipitated with cold TCA (Sigma). The cells were lysed with RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS). For immunoprecipitation, cell lysates were incubated with mouse anti-FLAG M2-agarose and then washed in PBS three times. For Western blot analysis, cell lysates, TCA-precipitated medium, or immunoprecipitated proteins were resuspended in SDS sample buffer containing 100 mM β-mercaptoethanol and were resolved by SDS-PAGE and transferred to a PVDF membrane.

**N-terminal Sequencing**—SW480 cells expressing PTK7-FLAG were preincubated in serum-free medium with 10 μM GM6001 or dimethyl sulfoxide for 30 min and then treated with 100 ng/ml PMA for 30 min. The cells were lysed with RIPA lysis buffer and immunoprecipitated with anti-FLAG M2-agarose. The precipitated C-terminal fragments of PTK7 were resolved by SDS-PAGE, transferred to a PVDF membrane, and stained with Coomassie Brilliant Blue. N-terminal sequences of the C-terminal fragments were analyzed by the Edman degradation method at the Tufts Core Facility (Tufts University, Medford, MA).

**Fractionation of Cytosolic and Nuclear Proteins**—SW480 cells expressing FLAG-PTK7 were pretreated with 10 μM DAPT for 30 min and then treated with 100 ng/ml PMA for 30 min. The cells were collected by scraping in PBS, spun down at 2,000 rpm for 5 min, resuspended in a hypotonic buffer (10 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl₂), and incubated on ice for 10 min. Nonidet P-40 was then added to a final concentration of 0.625%, and the lysate was incubated on ice for 20 min. The lysate was centrifuged at 2,000 rpm for 5 min to separate the cytosolic fraction from the nuclear pellet. The nuclear pellet was washed twice in hypotonic buffer, resuspended in SDS lysis buffer, and incubated for 30 min. The nuclear fraction was obtained by centrifugation at 13,000 rpm for 15 min.

**Immunofluorescence Staining and Confocal Microscopy**—SW480 cells expressing PTK7-CTF2-FLAG or transfected with a control vector were grown on poly-L-lysine-coated coverslips. SW480 cells expressing PTK7-CTF2-FLAG or transfected with an M2-agarose and then washed in PBS three times. For Western blot analysis, cell lysates, TCA-precipitated medium, or immunoprecipitated proteins were resuspended in SDS sample buffer containing 100 mM β-mercaptoethanol and were resolved by SDS-PAGE and transferred to a PVDF membrane.

**Cell Migration Assay**—Cell migration was assayed using modified Boyden chambers (8-μm pore size, Costar Transwell filters; Corning-Costar, Lowell, MA) coated with 0.1% gelatin. Subconfluent cells were incubated in serum-free medium for 24 h. The 1 × 10⁵ cells in 100 μl of serum-free medium were loaded on the upper chamber. DMEM (600 μl) containing 5% FBS served as a chemoattractant in the lower chamber. After 24 h, cells in the upper surface of the upper chamber were removed with cotton swabs. Cells that had migrated to the lower surface of the upper chamber were stained with hematoxylin and eosin and counted under a light microscope.

**Anchorage-independent Colony Formation Assay**—Anchorage-independent colony formation was measured as described previously (38). Cells (5 × 10^⁴/well) were suspended in DMEM-10% FBS containing 0.35% Bacto agar (Difco, Sparks, MD) incubated at 42 °C and overlaid onto the solidified 0.5% agar layer containing DMEM-10% FBS. After 3 weeks of incubation, the number of colonies formed was counted with a microscope.

**RESULTS**

sPTK7-Ig1–7 Is Shed in Colon Cancer Cells—To examine whether shedding of PTK7 occurs in colon cancer cell lines, Western blot analysis with an antibody against the extracellular domain of PTK7 in various colon cancer cell lines (HCT-8, HCT-15, HCT-116, DLD-1, LoVo, HT-29, and SW480) and HEK293 cells was performed. We detected a 100-kDa band in the conditioned medium from colon cancer cells and HEK293 cells (Fig. 1A). A band of similar mass was observed in HEK293 cells ectopically expressing the sPTK7-His polypeptide. Considering that sPTK7-His contains all seven Ig loops in the extracellular domain of PTK7 in various colon cancer cell lines, the results indicate that the shed fragment of PTK7 in colon cancer cells should also contain all seven Ig loops in the extracellular domain. Thus, it was named sPTK7-Ig1–7.

Phorbol esters such as PMA are potent activators of PKC and have been reported to stimulate shedding of diverse proteins such as IL-6R, ErbB4, and TNF-α (39). We thus analyzed
whether PMA increases shedding of sPTK7-Ig1–7 in SW480 cells. PMA treatment enhanced release of sPTK7-Ig1–7 into conditioned medium when compared with mock- or dimethyl sulfoxide-treated cells (Fig. 1B). The apparent molecular mass of sPTK7-Ig1–7 did not change in the presence of PMA (Fig. 1B).

**A Metalloprotease Contributes to sPTK7-Ig1–7 Shedding**—To address which protease mediates PTK7 shedding, we analyzed PTK7 shedding in the presence of various protease inhibitors in SW480 cells. A panmetalloprotease inhibitor (GM6001) and an MMP and ADAM17 inhibitor (TAPI-1) blocked constitutive shedding of PTK7, but inhibitors of serine proteases (AEBSF), cysteine and serine proteases (leupeptin), and cysteine proteases (E-64) did not (Fig. 2A). Like constitutive PTK7 shedding, PMA-induced PTK7 shedding was also inhibited by the metalloprotease inhibitors, GM6001 and TAPI-1, but not by other protease inhibitors (Fig. 2B). Thus, the shed fragment size and metalloprotease requirement were the same in constitutive or PMA-induced sPTK7-Ig1–7 shedding.

**Both the Extracellular Domain and Transmembrane Domain of PTK7 Are Cleaved**—To identify the cleavage site of PTK7 shedding, PTK7-FLAG was stably expressed in SW480 cells. SW480 cells expressing PTK7-FLAG were stimulated with PMA in the presence or absence of GM6001, and PTK7 shedding was analyzed. Immunoprecipitation with an anti-FLAG antibody followed by Western blot analysis revealed the presence of two CTFs of PTK7, which we named PTK7-CTF1-FLAG and PTK7-CTF2-FLAG (Fig. 3A).

To identify the cleavage sites, the CTF bands that were detected in Coomassie Brilliant Blue-stained SDS gels (Fig. 3A) were subjected to N-terminal sequencing by the Edman degradation method. The N-terminal sequences of PTK7-CTF1-FLAG and PTK7-CTF2-FLAG were $^{690}$SEGPG and $^{722}$LMFYX, respectively (Fig. 3B). The amino acid residue at the X position was Cys which could not be detected by this method. This finding suggests that PTK7 is cleaved at two different positions; between amino acids Glu$^{689}$ and Ser$^{690}$ near the C terminus of the extracellular domain (Ala$^{31}$ to Gln$^{703}$) and between amino acids Gly$^{721}$ and Leu$^{722}$ near the C terminus of a transmembrane segment (Thr$^{704}$ to Tyr$^{725}$). Therefore, sPTK7-Ig1–7 that spans Ala$^{31}$ to Glu$^{689}$ (Fig. 3B) is shed into the extracellular space, and PTK7-CTF2-FLAG which spans Leu$^{722}$ to Pro$^{1070}$ is likely released into the cytosol.

**sPTK7-Ig1–7 Shedding Is Mediated by ADAM17**—To characterize which metalloprotease is involved, sPTK7-Ig1–7 shedding was analyzed in the presence of TIMPs, which are major physiological metalloprotease inhibitors. SW480 cells, in which one of four TIMPs was stably expressed, were stimulated with PMA to enhance sPTK7-Ig1–7 shedding. Shedding of sPTK7-Ig1–7 was efficiently suppressed by TIMP-3, but not by TIMP-1, TIMP-2, or TIMP-4 (Fig. 4A). TIMP-3 inhibits various MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14, and MMP-15) (40) and ADAM10 and ADMA17. However, the MMPs inhibited by TIMP-3 are also inhibited by at least one other TIMP that cannot block PTK7 shedding, suggesting that the sheddase is ADAM10 and/or
ADAM17 and not an MMP. However, TIMP-1 inhibits ADAM10 but not ADAM17 and does not prevent PTK7 shedding (41, 42), thus indicating that ADAM17 is likely the PTK7 sheddase.

In addition, a synthetic ADAM inhibitor GW280264X, which inhibits both ADAM17 and ADAM10, inhibits sPTK7-Ig1–7 shedding in a dose-dependent manner in SW480 cells with or without PMA stimulation (Fig. 4, B and C). Another ADAM inhibitor GI254023X, which inhibits ADAM10 about 100 times more than ADAM17 (35, 36), is a poor inhibitor of sPTK7-Ig1–7 shedding (Fig. 4, B and C). Moreover, siRNA-mediated ADAM17 knockdown reduced PMA-induced sPTK7-Ig1–7 shedding in SW480 cells, but ADAM10 knockdown did not (Fig. 4D). These results demonstrate that ADAM17 contributes to PTK7 shedding.

**Generation of PTK7-CTF2 Is Dependent on γ-Secretase Activity**—As shown above, PTK7-CTF2 was generated by proteolytic cleavage within the transmembrane segment (Fig. 3B). Many receptor proteins that are cleaved in the extracellular domain by ADAMs are processed within a transmembrane segment by a γ-secretase complex (43). To analyze whether a γ-secretase complex is involved in PTK7 processing, generation of PTK7-CTF2 was analyzed in SW480 cells expressing PTK7-FLAG in the presence of the γ-secretase inhibitors, DAPT and l-685458, with or without GM6001. Treatment with DAPT or l-685458 completely blocked the generation of PTK7-CTF2-FLAG (Fig. 5). Interestingly, GM6001 alone prevented the generation of PTK7-CTF2 as well as production of PTK7-CTF1. These results indicate that sequential cleavage of PTK7 by ADAM17 and γ-secretase releases sPTK7-Ig1–7 into the extracellular space and PTK7-CTF2 into the cytoplasm.

**PTK7-CTF2 Is Localized Mainly in the Nucleus**—In an attempt to determine a role for PTK7-CTF2, we analyzed its intracellular localization of PTK7-CTF2-FLAG in SW480 cells using two different methods. First, SW480 cells expressing PTK7-FLAG were separated into cytosolic and nuclear fractions. PTK7-CTF1-FLAG was found in the cytosolic fraction, but PTK7-CTF2-FLAG was mainly in the nuclear fraction (Fig. 6A). Second, immunofluorescence demonstrated that PTK7-CTF2-FLAG expressed in SW480 cells is mainly localized to the nucleus (Fig. 6B).
PTK7-CTF2 Expression Increases Cell Proliferation and Migration—To investigate further the function of nuclear PTK7-CTF2, we carried out several assays to monitor biological functions. An MTT assay showed that SW480 cells expressing PTK7-CTF2-FLAG (Fig. 7A) grow up to two times faster than SW480 cells transfected with an empty vector (Fig. 7B). A migration assay using a Boyden chamber showed that SW480 cells expressing PTK7-CTF2-FLAG migrate approximately four times faster than control SW480 cells (Fig. 7C). Further, anchorage-independent colony formation assays indicated that expression of PTK7-CTF2-FLAG enhanced colony formation in soft agar, with almost twice as many colonies as the vector control (Fig. 7D). Together, these findings suggest that PTK7-CTF2 translocation to the nucleus will enhance the oncogenic potential of SW480 cells.

DISCUSSION

In this study, we found shed PTK7 in the medium from multiple colon cancer cell lines. The shed polypeptide is ~100 kDa and includes all seven Ig loops of the extracellular domain of PTK7. Treatment with PMA enhances shedding, but does not alter the size of the shed fragment in SW480 cells. Shedding was inhibited by a panmetalloprotease inhibitor, GM6001, and the MMP/ADAM inhibitors, TAPI-1 and TIMP-3, but not by other TIMPs or nonmetalloprotease inhibitors. In addition, an ADAM10/17 inhibitor, GW280264X, inhibited PTK7 shedding whereas another ADAM inhibitor that is 100 times more selective for ADAM10 than ADAM17, GI254023X, poorly inhibited, in SW480 cells with or without PMA stimulation (Fig. 4) and in other colon cancer cells (data not shown). Furthermore, ADAM17 knockdown reduced PMA-induced sPTK7-Ig1–7 shedding. These data demonstrate that ADAM17 should be a sheddase of PTK7.

Among the 21 ADAMs identified in the human genome, 13 members are proteolytically active. ADAM17 is one of the proteolytically active members (26). Expression of ADAM17 is increased in various cancers including breast cancer (44), colorectal cancer (45), pancreatic cancer (46), prostate cancer (47), renal cancer (48), and hepatocellular cancer (49). Overexpression of ADAM17 in breast cancer cells increased in vitro invasion and proliferation (50). Also, silencing of ADAM17 suppressed tumor formation by inhibiting ADAM17-mediated TGF-α release, a ligand for the EGF receptor, in renal carcinoma cells (51). Therefore, ADAM17 contributes to tumorigenesis and metastasis by promoting cell proliferation, adhesion, migration, and invasion (52–54).

During our study, Golubkov et al. (34) reported that PTK7 levels were reduced in breast cancer cells overexpressing MMP-14 and that sPTK7-Ig1–6 shed from PTK7 was observed in HT1080 cells overexpressing MMP-14. We observed a 73-kDa band, which may correspond to sPTK7-Ig1–6, at low level in culture medium of some colon cancer cells such as HT-29 cells (Fig. 1A). However, the major PTK7 shed product detected was 100-kDa band corresponding to sPTK7-Ig1–7 rather than 73-kDa band. These results strongly suggest that at least in colon cancer cells ADAM17 is a main sheddase of PTK7.
PTK7 Sheding and the Oncogenic Role of Its Cytosolic Domain

thus that PTK7 is sequentially cleaved by ADAM17 and γ-secretase.

Intracellular domains of type I transmembrane receptors cleaved by γ-secretases are known to exert biological effects at other sites within the cell. The most well characterized function of such intracellular domains is transcriptional regulation in the nucleus. For example, the intracellular domain of ErbB4 complexed with the signaling protein TAB2, and the co-repressor N-CoR translocates to the nucleus and represses GFAP and S100β promoters (30). Likewise, PTK7-CTF2 is localized mainly in the nucleus. Ectopic expression of PTK7-CTF2 increases proliferation, migration, and anchorage-independent colony formation of SW480 cells. Thus, PTK7-CTF2 translocation from the plasma membrane to the nucleus likely regulates transcription, thus enhancing tumor generation and progression.

Accumulated data suggest that PTK7 is up-regulated in various cancers (2, 15–20) and that its expression promotes proliferation, survival, migration, and invasion (15, 20–22). We have also shown that treatment with sPTK7-Ig1–7 or PTK7 knockdown inhibits VEGF-induced migration, invasion, tube formation of HUVECs, and VEGF-induced angiogenesis in vivo (33). However, it has also been reported that PTK7 down-regulates actin cytoskeleton organization and actomyosin contraction and that sPTK7-Ig1–6 enhances cell locomotion and invasion in HT-1080 cells by reverting PTK7 functions (34). The functional differences between sPTK7-Ig1–7 and sPTK7-Ig1–6 could result from the presence of the seventh Ig loop in sPTK7-Ig1–7 or may be dependent on the cell type studied. Nonetheless, sPTK7-Ig1–7 is thought to act as a tumor suppressor by counteracting PTK7. However, to neutralize PTK7 function, high concentrations (>53 μM) of sPTK7 were required (33). Moreover, shed sPTK7 would diffuse out into extracellular space, and so we assume that the effect of shed sPTK7 would not be significant in cancer tissues. In contrast, another processing product of PTK7, PTK7-CTF2, is able to be effectively concentrated in the nucleus and thus activate signaling pathways to promote tumorigenesis and metastasis. Therefore, although it seems that PTK7 is oncogenic as an intact molecule, it maintains its oncogenic properties through the generation of PTK7-CTF2 in the malignant environment.

Here, we have shown that PTK7 is sequentially processed by ADAM17 at the C-terminal region of the extracellular domain and then by γ-secretase within the transmembrane segment and that the resulting fragments sPTK7-Ig1–7 and PTK7-CTF2 are released into the extracellular space and nucleus, respectively. We also showed that PTK7-CTF2 localized to the nucleus can increase proliferation, migration, and anchorage-independent colony formation. Therefore, in addition to the known oncogenic role of the intact PTK7 molecule, we add a novel role of PTK7 upon its shedding: PTK7-CTF2 translocates into nucleus and enhances oncogenic properties of the cell.

REFERENCES

1. Lee, S. T., Strunk, K. M., and Spritz, R. A. (1993) A survey of protein-tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene 8, 3403–3410

2. Mossie, K., Jallal, B., Alves, F., Sures, I., Plowman, G. D., and Ullrich, A. (1995) Colon carcinoma kinase-4 defines a new subclass of the receptor for N-CoR translocates to the nucleus and represses GFAP and S100β promoters (30). Likewise, PTK7-CTF2 is localized mainly in the nucleus. Ectopic expression of PTK7-CTF2 increases proliferation, migration, and anchorage-independent colony formation of SW480 cells. Thus, PTK7-CTF2 translocation from the plasma membrane to the nucleus likely regulates transcription, thus enhancing tumor generation and progression.

Accumulated data suggest that PTK7 is up-regulated in various cancers (2, 15–20) and that its expression promotes proliferation, survival, migration, and invasion (15, 20–22). We have also shown that treatment with sPTK7-Ig1–7 or PTK7 knockdown inhibits VEGF-induced migration, invasion, tube formation of HUVECs, and VEGF-induced angiogenesis in vivo (33). However, it has also been reported that PTK7 down-regulates actin cytoskeleton organization and actomyosin contraction and that sPTK7-Ig1–6 enhances cell locomotion and invasion in HT-1080 cells by reverting PTK7 functions (34). The functional differences between sPTK7-Ig1–7 and sPTK7-Ig1–6 could result from the presence of the seventh Ig loop in sPTK7-Ig1–7 or may be dependent on the cell type studied. Nonetheless, sPTK7-Ig1–7 is thought to act as a tumor suppressor by counteracting PTK7. However, to neutralize PTK7 function, high concentrations (>53 μM) of sPTK7 were required (33). Moreover, shed sPTK7 would diffuse out into extracellular space, and so we assume that the effect of shed sPTK7 would not be significant in cancer tissues. In contrast, another processing product of PTK7, PTK7-CTF2, is able to be effectively concentrated in the nucleus and thus activate signaling pathways to promote tumorigenesis and metastasis. Therefore, although it seems that PTK7 is oncogenic as an intact molecule, it maintains its oncogenic properties through the generation of PTK7-CTF2 in the malignant environment.

Here, we have shown that PTK7 is sequentially processed by ADAM17 at the C-terminal region of the extracellular domain and then by γ-secretase within the transmembrane segment and that the resulting fragments sPTK7-Ig1–7 and PTK7-CTF2 are released into the extracellular space and nucleus, respectively. We also showed that PTK7-CTF2 localized to the nucleus can increase proliferation, migration, and anchorage-independent colony formation. Therefore, in addition to the known oncogenic role of the intact PTK7 molecule, we add a novel role of PTK7 upon its shedding: PTK7-CTF2 translocates into nucleus and enhances oncogenic properties of the cell.
Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. *Cancer Res.* **71**, 2697–2705.

21. Prebet, T., Lhoumeau, A. C., Arnoulet, C., Aulas, A., Marchetto, S., Audebert, S., Puppo, F., Chabannon, C., Saincy, D., Santoni, M. J., Sebbagh, M., Summerour, V., Huon, Y., Shin, W. S., Lee, S. T., Esterni, B., Vey, N., and Borg, J. P. (2010) The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. *Blood* **116**, 2315–2323.

22. Meng, L., Sefah, K., O’Donoghue, M. B., Zhu, G., Shangguan, D., Noorali, A., Chen, Y., Zhou, L., and Tan, W. (2010) Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis via mitochondrial pathway. *PLoS One* **5**, e14018.

23. Gronborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R., Reddy, R., Sato, N., Molina, H., Jensen, O. N., Hruban, R. H., Goggins, M. G., Maitra, A., and Pandey, A. (2006) Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. *Mol. Cell Proteomics* **5**, 162–171.

24. Xun, H., Lü, B., Zhang, J., Wu, M., Huang, Q., Wu, Q., Sheng, H., Wu, D., Hu, J., and Lai, M. (2010) Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. *J. Proteome Res.* **9**, 545–555.

25. Dello Sbarba, P., and Rovida, E. (2002) Transmodulation of cell surface regulatory molecules via ectodomain shedding. *Biol. Chem.* **383**, 69 – 83.

26. Edwards, D. R., Handsley, M. M., and Pennington, C. J. (2008) The ADAM metalloproteinases. *Mol. Aspects Med.* **29**, 258–289.

27. Reiss, K., and Safigt, S. (2009) The “a disintegrin and metalloprotease” (ADAM) family of sheddases: physiological and cellular functions. *Semin. Cell Dev. Biol.* **20**, 126–137.

28. Rahimi, N., Golde, T. E., and Meyer, R. D. (2009) Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/Flt1 in leukemic cancer cells. *Cancer Res.* **69**, 2607–2614.

29. Schroeter, E. H., Kisslinger, J. A., and Kopan, R. (1998) Notch-1 signaling requires ligand-induced proteolytic release of intracellular domain. *Nature* **393**, 382–386.

30. Sardi, S. P., Murtie, J., Koirala, S., Patten, B. A., and Corfas, G. (2006) Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogliogenesis in the developing brain. *Cell* **127**, 185–197.

31. Georgakopoulos, A., Litterst, C., Gherzi, E., Baki, L., Xu, C., Serban, G., and Robakis, N. K. (2006) Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. *EMBO J.* **25**, 1242–1252.

32. Marambaud, P., Shio, J., Serban, G., Georgakopoulos, A., Sarner, S., Nagy, V., Baki, L., Wen, P., Efthimiopoulos, S., Shao, Z., Wisniewski, T., and Robakis, N. K. (2002) A presenilin-1 γ-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. *EMBO J.* **21**, 1948–1956.

33. Shin, W. S., Maeng, Y. S., Jung, J. W., Min, J. K., Kwon, Y. G., and Lee, S. T. (2008) Soluble PTK7 inhibits tube formation, migration, and invasion of endothelial cells and angiogenesis. *Biochem. Biophys. Res. Commun.* **371**, 793–798.

34. Golubkov, V. S., Chekanov, A. V., Cieplak, P., Aleshin, A. E., Chernov, A. V., Zhu, W., Radichev, I. A., Zhang, D., Dong, P. D., and Strongin, A. Y. (2010) The Wnt/planar cell polarity-protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis. *J. Biol. Chem.* **285**, 35740–35749.

35. Hundtashaw, C., Misztela, D., Berkhout, T. A., Broadway, N., Safigt, P., Reiss, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V., Kallen, K. J., Rose-John, S., and Ludwig, A. (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. *Blood* **102**, 1186–1195.

36. Ludwig, A., Hundtashaw, C., Lambert, M. H., Broadway, N., Andrews, R. C., Bickett, D. M., Leenstzer, M. A., and Becherer, J. D. (2005) Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. *Comb. Chem. High Technol.* **8**, 95–103.

37. Toyoftu, T., Zhang, H., Kumanogoh, A., Takegahara, N., Suto, F., Kamei, J., Aoki, K., Yahuki, M., Hori, M., Fujisawa, H., and Kikutani, H. (2004) Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. *Genes Dev.* **18**, 435–447.

38. Wagner, G., Peradziryi, H., Wehner, P., and Borchers, A. (2010) Plexin-A1 interacts with PTK7 and is required for neural crest migration. *Biochem. Biophys. Res. Commun.* **402**, 402–407.

39. Lu, X., Borchers, A. G., Jolicoeur, C., Rayburn, H., Baker, J. C., and Tessier-Lavigne, M. (2004) PTK7/CCX-4 is a novel regulator of planar cell polarity in vertebrates. *Nature* **430**, 93–98.

40. Shnitsar, I., and Borchers, A. (2008) PTK7 recruits dsh to regulate neural crest migration. *Development* **135**, 4015–4024.

41. Wehner, P., Shnitsar, I., Urlaub, H., and Borchers, A. (2011) RACK1 is a versatile regulator of cell-cell communication. *Arch. Biochem. Biophys.* **524**, 71–76.

42. Pulido, D., Campuzano, S., Koda, T., Modolell, J., and Barbacid, M. (1992) Dtrk, a Drosophila gene related to the trk family of neurotrophin receptors, encodes a novel class of neural cell adhesion molecule. *EMBO J.* **11**, 391–404.

43. Winberg, M. L., Tamagnone, L., Bai, J., Comoglio, P. M., Montell, D., and Goodman, C. S. (2001) The transmembrane protein off-track associates with Plexins and functions downstream of semaphorin signaling during axon guidance. *Neuron* **32**, 53–62.

44. Park, S. K., Lee, H. S., and Lee, S. T. (1996) Characterization of the human full-length PTK7 cDNA encoding a receptor protein tyrosine kinase-like molecule closely related to chick KLG. *J. Biochem.* **119**, 235–239.

45. Jung, J. W., Shin, W. S., Song, I., and Lee, S. T. (2004) Cloning and characterization of the full-length mouse Ptk7 cDNA encoding a defective receptor protein tyrosine kinase. *Gene* **328**, 75–84.

46. Peradziryi, H., Tolwinski, N. S., and Borchers, A. (2012) The many roles of PTK7: a versatile regulator of cell-cell communication. *J. Biol. Chem.* **287**, 23999–24006.
PTK7 Shedding and the Oncogenic Role of Its Cytosolic Domain

JULY 20, 2012 • VOLUME 287 • NUMBER 30
JOURNAL OF BIOLOGICAL CHEMISTRY

37. Wigler, M., Sweet, R., Sim, G. K., Wold, B., Pellicer, A., Lacy, E., Maniatis, T., Silverstein, S., and Axel, R. (1992) Transformation of mammalian cells with genes from prokaryotes and eukaryotes. 1979. BioTechnology 24, 444–452
38. Kim, H. and Lee, S. T. (2005) An intramolecular interaction between SH2-kinase linker and kinase domain is essential for the catalytic activity of protein-tyrosine kinase-6. J. Biol. Chem. 280, 28973–28980
39. Huovila, A. P., Turner, A. J., Pelto-Huikko, M., Kärkkäinen, I., and Ortiz, R. M. (2005) Shedding light on ADAM metallopeptinases. Trends Biochem. Sci. 30, 413–422
40. Zhao, H., Bernardo, M. M., Osenkowski, P., Sohail, A., Pei, D., Nagase, H., Kashiwagi, M., Soloway, P. D., DeClerck, Y. A., and Fridman, R. (2004) Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation. J. Biol. Chem. 279, 8592–8601
41. Amour, A., Slocombe, P. M., Webster, A., Butler, M., Knight, C. G., Smith, B. J., Stephens, P. E., Shelley, C., Hutton, M., Knäuper, V., Docherty, A. J., and Murphy, G. (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435, 39–44
42. Amour, A., Knight, C. G., English, W. R., Webster, A., Slocombe, P. M., Knäuper, V., Docherty, A. J., Becherer, I. D., Blobel, C. P., and Murphy, G. (2002) The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 524, 154–158
43. Haapasalo, A., and Kovacs, D. M. (2011) The many substrates of presenilin/γ-secretase. J. Alzheimers Dis. 25, 3–28
44. Lendreck, U., Kohl, J., Arndt, M., Carl-McGrath, S., Donat, H., and Röcken, C. (2005) Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J. Cancer Res. Clin. Oncol. 131, 41–48
45. Blanchot-Jossic, F., Jarry, A., Masson, D., Bach-Ngohou, K., Paineau, J., Denis, M. G., Laboisse, C. L., and Mosnier, J. F. (2005) Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J. Pathol. 207, 156–163
46. Ringel, J., Jesnowski, R., Moniaux, N., Lütgges, J., Choudhury, A., Batra, S. K., Kloppel, G., and Lohr, M. (2006) Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-α-converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res. 66, 9045–9053
47. Karan, D., Lin, F. C., Bryan, M., Ringel, J., Moniaux, N., Lin, M. F., and Batra, S. K. (2003) Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int. J. Oncol. 23, 1365–1371
48. Roemer, A., Schwettmann, L., Jung, M., Stephan, C., Roigas, J., Kristiansen, G., Loening, S. A., Lichtinghagen, R., and Jung, K. (2004) The membrane proteases ADAMs and hepsin are differentially expressed in renal cell carcinoma: are they potential tumor markers? J. Urol. 172, 2162–2166
49. Ding, X., Yang, L. Y., Huang, G. W., Wang, W., and Lu, W. Q. (2004) ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J. Gastroenterol. 10, 2735–2739
50. McGowan, P. M., Ryan, B. M., Hill, A. D., McDermott, E., O’Higgins, N., and Duffy, M. J. (2007) ADAM17 expression in breast cancer correlates with variables of tumor progression. Clin. Cancer Res. 13, 2335–2343
51. Franovic, A., Robert, J., Smith, K., Kurban, G., Pause, A., Gunaratnam, L., and Lee, S. (2006) Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res. 66, 8083–8090
52. Murphy, G. (2008) The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 8, 929–941
53. Roy, R., Yang, J., and Moses, M. A. (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27, 5287–5297
54. Duffy, M. J., Mullaney, M., O’Donovan, N., Sukor, S., Crown, J., Pierce, A., and McGowan, P. M. (2011) The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin. Proteomics 8, 9
55. Beel, A. J., and Sanders, C. R. (2008) Substrate specificity of γ-secretase and other intramembrane proteases. Cell Mol. Life Sci. 65, 1311–1334
56. Weihofen, A., and Martoglio, B. (2003) Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. Trends Cell Biol. 13, 71–78